Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 1;33(15):2410-2412.
doi: 10.1093/bioinformatics/btx161.

CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets

Åsmund Flobak  1 , Miguel Vazquez  1   2 , Astrid Lægreid  1 , Alfonso Valencia  2
Affiliations

CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets

Åsmund Flobak et al. Bioinformatics. .

Abstract

Motivation: Drug synergies are sought to identify combinations of drugs particularly beneficial. User-friendly software solutions that can assist analysis of large-scale datasets are required.

Results: CImbinator is a web-service that can aid in batch-wise and in-depth analyzes of data from small-scale and large-scale drug combination screens. CImbinator offers to quantify drug combination effects, using both the commonly employed median effect equation, as well as advanced experimental mathematical models describing dose response relationships.

Availability and implementation: CImbinator is written in Ruby and R. It uses the R package drc for advanced drug response modeling. CImbinator is available at http://cimbinator.bioinfo.cnio.es , the source-code is open and available at https://github.com/Rbbt-Workflows/combination_index . A Docker image is also available at https://hub.docker.com/r/mikisvaz/rbbt-ci_mbinator/ .

Contact: asmund.flobak@ntnu.no or miguel.vazquez@cnio.es.

Supplementary information: Supplementary data are available at Bioinformatics online.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
An intuitive user inter-face presents the drug synergy assessment for each drug combination in a birds eye overview matrix (a), with color-coded bars for each drug combination to allow for a quick evaluation of synergies (green = synergy, yellow = additivity, red = antagonism). Individual drug combination responses can be inspected more closely with dose–response relationships for each single drug and the drug combination (b), including combination indexes as confidence bands. See Supplementary Material and online help-section for further information
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Axelrod M. et al. (2013) Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget, 4, 622–635. - PMC - PubMed
    1. Chou T.-C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res., 70, 440–446. - PubMed
    1. Crystal A.S. et al. (2014) Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science, 346, 1480–1486. - PMC - PubMed
    1. Di Veroli G.Y. et al. (2016) Combenefit: An interactive platform for the analysis and visualisation of drug combinations. Bioinformatics, 32, 2866–2868. - PMC - PubMed
    1. Greco W.R. et al. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47, 331–385. - PubMed

Substances